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was irradiated at six different depths of a 6 cm SOBP using a field size 
of 10 x 15 mm2 including the segments C1-C6. The corresponding 
linear energy transfer (LET)-values ranged between 16 and 99 
keV/µm. Irradiations were performed with single and split doses using 
a series of increasing dose levels. Endpoint of the study was the 
occurrence of forelimb paresis grade II within 300 days. Rats with 
paresis grade II were sacrificed, the cervical spinal cord was taken out 
and processed for histological examinations.  
Results: Preliminary analysis of the data shows that with increasing 
LET the RBE-values for single and split doses increase. In general, the 
TD50 (dose at 50 % effect probability) values decrease with increasing 
LET. Compared to the historical data [2] the TD50-values in the 
plateau region are comparable within experimental uncertainties. 
With increasing LET the fractionation ratio (D50 of 2 vs. 1 fraction) 
decreases suggesting an increasing α/β-ratio. 
 The latency time decreases with increasing LET. It is significantly 
shorter for peak irradiation than for plateau irradiation. Latency times 
for peak irradiations were found to be dose dependent while no dose 
dependence was observed for plateau irradiations. 
Conclusions: On the basis of this preliminary analysis the LET effect is 
clearly visible, meaning that high LET irradiations are more effective 
than low LET irradiations. 
 With these studies we extent the database on experimental tolerance 
doses and RBE-values of the rat cervical spinal cord. The data allow to 
study and assess accuracy and limitations of RBE-models by comparing 
measured and calculated RBE-values. Further experiments with six 
fractions will be performed, which will allow a more robust 
determination of α/β-ratio as a function of LET. To elucidate the 
mechanisms of the radiation damage, an additional MRI and histology-
based longitudinal study is ongoing.  
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Purpose/Objective: Urethral stricture is one of the known 
complications in the treatment for prostate cancer, regardless the 
particular therapeutic modality. We reviewed our experience in 
patients treated with high dose rate (HDR) brachytherapy for prostate 
cancer, identifying incidence, timing, and outcomes in those who 
developed urethral stricture after the procedure. We also attempted 
to seek a solution in treatment technique and planning to prevent 
such occurrence. 
Materials and Methods: Since 1997, 448 patients had undergone HDR 
brachytherapy for clinically localized prostate cancer in our 
institution. Over 95% of our patients had intermediate or high risk 
tumor and practically all patients received neo-adjuvant hormone 
therapy. The HDR protocol typically called for 3 treatment sessions 
with one overnight stay. A single radioactive iridium-192 source was 
used with a nominal activity of 370 GBq. The prescribed dose of 6 Gy 
per session covered at least 95% of the prostate volume (PTV). All 
patients received supplementary external beam radiation therapy 
following completion of the brachytherapy procedure, and external 
beam dose ranged from 45 Gy to 50.4 Gy (median 50 Gy) using 
conventional fractionation schemes. For the past two years, the 
brachytherapy regimen was changed to a single fraction of 13 Gy, thus 
all patients could be treated on an outpatient basis. All urethral 
strictures were diagnosed cystoscopically. Patient demographics, 
operative, and postoperative data were reviewed. 
Results: Overall survival rate of the entire cohort of our patients was 
98.6%, with a mean follow-up of 55 months. Two patients died from 
metastasis and 2 other patients died from unrelated causes. Twenty-
two patients (5%) have developed urethral strictures to-date. The 
median time between radiation therapy and the diagnosis of urethral 
stricture was 4 years (range 1-8 years), with nearly all strictures 
located in the bulbomembranous urethra. At last follow-up, 2 of the 
22 patients had a patent urethra. The remaining 20 patients did not 
have a stable patent urethra. Nine (41%) of these patients required a 
urethral dilation schedule, and 3 patients (14%) needed either 
suprapubic tube or urethral catheter drainage. Five patients (23%) 
required multiple endoscopic procedures or dilations, while 3 patients 
(14%) required dilation at last follow-up.  
Conclusions: Risk of urethral stricture from HDR brachytherapy for 
clinically localized prostate cancer appears real. Although incidence 
of radiation induced urethral stricture remains relatively low, it could 
result in significant morbidity for the patients. With improved 
catheter placement technique and meticulous treatment planning 
accomplishing 'donut' dosimetry presently, we could expect reduced 
incidence of this complication after HDR brachytherapy for prostate 
cancer. 
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Purpose/Objective: Inverse treatment planning requires constraints 
for adequate dose coverage of the prostate and limitation of the dose 
to the organs at risk. The purpose of this study was to investigate if 
there is a relation between the dose to the different sub-segments of 
the lower urinary tract and enhanced lower urinary tract symptoms 
(LUTS) after low dose rate brachytherapy with I-125 seeds, and if 
there is, to determine a dose constraint for treatment planning 
purposes. 
Materials and Methods:  
  
his study involved 225 patients treated for prostate cancer with I-125 
seeds with a prescribed dose of 145 Gy. The patients filled in an 
International Prostate Symptom Score (IPSS) questionnaire before 
(baseline) and 1 week, 6 weeks and 3 months after the implantation 
of the seeds. These post-implant scores cover the time period when 
LUTS levels are expected to be maximal. On post-implant fused CT-
TRUS images the prostate, the urethra, the bladder wall, the bladder 
neck and the external sphincter were delineated (see figure) and 
cumulative dose volume histograms (CDVHs) were determined. The 
bladder neck was defined by the urethral orifice connecting the 
bladder and the prostatic urethra plus a 5 mm margin in all directions. 
The external sphincter was defined by that part of the urethra that 
connects the prostatic and the membranous trajectory plus a 5 mm 
margin in all directions. The endpoint was the mean IPSS during the 
first 3 months after the treatment. For binary analysis the patients 
were stratified in a group with enhanced LUTS (mean post-implant 
IPSS ≥12 and mean increase over baseline IPSS ≥6, or catheter depen-
dency) and a group with non-enhanced LUTS. 
Results: Multivariate linear regression analysis revealed that the dose 
to 0.5 cm3 of the bladder neck 'D0.5cc-blne' (p=0.002), the prostate 
volume prior to treatment 'Vpr -0' (p=0.005) and the baseline IPSS 
(p<0.001) were independently correlated with the mean IPSS. When 
'high' is defined as ≥175 Gy and ≥42 cm3 for D0.5cc-blne and Vpr -0, 
respectively, and 'low' as < than these values, 68% of the patients with 
a high D0.5cc-blne and a high Vpr -0 suffered from enhanced LUTS, 
against 31%, 36% and 23% for the combinations high-low, low-high and 
low-low of these parameters, respectively (p<0.0001).  
Conclusions: Prostate volume and dose to the bladder neck are 
correlated with post-implant IPSS. A combination of a large prostate 
and a high dose to the bladder neck is highly predictive for enhanced 
early LUTS. To minimize the incidence of enhanced LUTS, D0.5cc-blne 
should be constrained to a maximum value of 175 Gy during the 
treatment planning process. 
 
 
 
 
 
 
